UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy...
Major Shareholder Will NOT Vote for Merger; Says 'Shareholders Have Already Spoken' by Rejecting Tender Offer at $5.60 per Share NEW YORK, Sept...
Bioenvision, Inc. (Nasdaq:BIVN) today announced an update on the status of its Marketing Authorization Application to the...
OKLAHOMA CITY, July 27 /PRNewswire/ -- On July 13, 2007, a class action lawsuit was filed in the United States District Court for the Southern...
Bioenvision, Inc. (Nasdaq:BIVN) today announced that it has been named as a defendant in a securities class action lawsuit filed...
Bioenvision, Inc. (Nasdaq:BIVN) today announced that Dr. Andrew N. Schiff and Mr. Steven A. Elms have resigned from the Company?s...
In the news release, Genzyme Completes Tender Offer to Acquire Bioenvision, Inc., issued earlier today by Genzyme Corporation over PR Newswire...
Proxy Statement to Be Prepared for Shareholder Meeting on Merger CAMBRIDGE, Mass., July 10 /PRNewswire-FirstCall/ -- Genzyme Corporation...
Waives Minimum Tender Condition; 100 Percent of Preferred Shares Now Tendered CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Genzyme...
Request for Preliminary Injunction to Prevent Transaction is Withdrawn CAMBRIDGE, Mass., June 27 /PRNewswire-FirstCall/ -- Genzyme Corporation...
To Gain Exclusive, Worldwide Rights to Clofarabine CAMBRIDGE, Mass. and NEW YORK, May 29 /PRNewswire-FirstCall/ -- Genzyme Corporation...
Bioenvision, Inc. (Nasdaq: BIVN) today announced financial results for the third quarter ended March 31, 2007. In the third...
Bioenvision, Inc. (Nasdaq: BIVN) announced today that it has received an aggregate of $7.4 million as a result of the exercise by...
Bioenvision, Inc. (Nasdaq: BIVN) today announced Jim Scibetta, chief financial officer of the Company, will be giving a...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.